Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
•
Hepatocellular Carcinoma
•
Liver Tumors
Would you consider ivosidenib for a patient with metastatic cholangiocarcinoma and an IDH1 mutation following progression on gem/cis and FOLFOX?
Does the Child Pugh score factor in your treatment decision, i.e. Child Pugh score C?
Related Questions
How would you approach the management of a patient with stage IIIA lung adenocarcinoma and multifocal hepatocellular carcinoma with Child-Pugh A cirrhosis?
What are your top takeaways from ASCO GI 2025?
What are your top takeaways in GI Cancers from ESMO 2024?
In patients with perihilar cholangiocarcinoma eligible for liver transplant, what is the protocol for neoadjuvant chemo-RT, particularly when brachytherapy is not available?
What are your first line treatment choices for metastatic combined HCC/Cholangiocarcinoma?
In a patient with amyloidosis and abnormal liver function but child Pugh A, would you still proceed with SABR for a liver metastasis?
Would you rechallenge with cabozantinib in a patient with HCC after the development of a 6 mm gastrohepatic fistula without perforation or communication with the peritoneal cavity?
How would you approach unexpected chemo breaks during planned neoadjuvant chemoradiation for esophageal adenocarcinoma?
Do you offer adjuvant chemotherapy to patients with rectal cancer who were on Watch-and-Wait, had local recurrence and underwent resection?
Would you offer adjuvant therapy for resected GB cancer > 6 months of surgery time if there are high risk features (pT3N0, positive margins, + PNI) and therapy was delayed due to hepatic abscess post operative?